To observe the clinical effect of Tongxinluo combined with Ticagrelor in the treatment of acute coronary syndrome(ACS)undergoing PCI.Methods:A total of 86 patients with ACS undergoing PCI admitted to the Fifth People's Hospital of Jinan from December 2017 to December 2018,were selected as the research objects and were randomly divided into an control group of 42 cases,and an observation group of 44 cases.The control group was given Ticagrelor treatment,and the observation group was given Tongxinluo on the basis of the control group,and the treatment lasted for 6 months.TIMI blood,LVEF,LVEDD,blood platelet aggregation rate,CK-MB,cTnI changes of the 2 groups were observed,and the cardiovascular events and adverse reactions were recorded.Results:After 6 months,postoperative TIMI blood flow of the 2 groups was significantly improved compared with that of preoperative(P<0.05).The observation group was superior to the control group(P<0.05).After 6 months,LVEF and LVEDD,platelet aggregation rate of the 2 groups after treatment were significantly improved than that before treatment(P<0.05),and the observation group was superior than the control group(P<0.05).In the 2 groups,the level of CK-MB and cTnI in 24 hours after operation were not significantly improved(P>0.05),and there were no significant differences between the groups(P>0.05); In the 2 groups,the CK-MB and cTnI in 72 hours after operation were significantly improved(P<0.05),the observation group was superior to the control group(P<0.05).Adverse cardiovascular events in the observaiton group were significantly lower than those in the control group(P<0.05),and there was no significant difference between the 2 groups(P>0.05).Conclusion:Tongxinluo combined with Ticagrelor in the treatment of acute coronary syndrome undergoing PCI has a significant effect,is helpful to postoperative recovery,reduce the occurrence of adverse cardiovascular events.It is worthy of popularization and application.